


FORM PTO-1449

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(37 CFR 1.98(b))



ATTY DOCKET NO.: 221.P1C SERIAL NO.: 09/187,763

APPLICANT: Arimilli et al.

FILING DATE: 11/6/98

GROUP ART UNIT: 1614

U.S. PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	ISSUE DATE	PATENTEE	CLASS/ SUBCLASS	FILING DATE
<i>MLA</i>	3,524,846	8/18/70	Moffatt et al.	—	6/2/67
↑	4,476,248	10/9/84	Gordon et al.	—	7/25/83
↓	4,816,570	3/28/89	Farquhar	536/27	
	4,968,788	11/6/90	Farquhar	536/27	1/23/89
	5,142,051	8/25/92	Holy et al	544/244	7/17/87
	5,177,064	1/5/93	Bodor	—	7/13/90
	5,208,221	5/4/93	Kim et al	514/81	11/29/90
	5,386,030	1/31/95	Kim et al	544/243	2/11/93
	5,506,347	4/9/96	Erion et al	—	2/3/94
	5,512,596	4/30/96	Kim et al.	514/568	9/2/94
↓	5,514,798	5/7/96	Bischofberger et al.	—	2/13/95
<i>MLA</i>	5,618,964	4/8/97	Cheng et al.	—	6/7/95

FOREIGN PATENT DOCUMENTS

EXAMR'S INITIALS	PATENT NO.	PUBLICATION DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES/NO
<i>MLA</i>	0 269 947 A1	6/8/88	EUROPE		
↑	0 369 409 A1	5/23/90	EUROPE		
↓	0 481 214 A1	4/22/92	EUROPE		
	0 632 048 A1	6/23/94	EUROPE		
	DE 41 38 584	5/27/93	GERMANY		
	EP 0 647 649 A1	4/12/95	EUROPE		
	WO 88/05438	7/28/88	PCT		
	WO 91/19721	12/26/91	PCT		
↓	WO 92/01698	2/6/92	PCT		
<i>MLA</i>	WO 92/09611	6/11/92	PCT		

EXAMINER

Michael G. Ambrose

DATE CONSIDERED

04/23/99

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(37 CFR 1.98(b))</small>	ATTY DOCKET NO.: 221.P1C SERIAL NO.: 09/187,763
	APPLICANT: Arimilli et al.
	FILING DATE: 11/6/98 GROUP ART UNIT: 1614

EXAMR'S INITIALS	PATENT NO.	PUBLICATION DATE	COUNTRY	CLASS/SUBCLASS	TRANSLATION YES/NO
mla	WO 92/13869	8/20/92	PCT	/	
↑	WO 94/03466	2/17/94	PCT		
	WO 94/03467	2/17/94	PCT		
	WO 95/07919	3/23/95	PCT		
↓	WO 95/07920	3/23/95	PCT		
mla	WO 96/18605	6/20/96	PCT		

OTHER DOCUMENTS

EXAMR'S INITIALS	ARTICLE
mla	Alexander et al., "Investigation of (Oxodioxolonyl)methyl Carbamates as Nonchiral Bioreversible Prodrug Moieties for Chiral Amines", 39:480-486, J MED CHEM, 1996
↑	Arimilli et al., "Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs", 8(6):557-567, ANTIVIRAL CHEM & CHEMO, 1997
	Arimilli et al., "Orally Bioavailable Acyclic Nucleoside Phosphonate Prodrugs: Adefovir Dipivoxil and Bis(POC)PMPA", Vol. 3 (accepted for publication), ADV ANTIVIRAL DRUG DESIGN, 1998
	Benzaria et al., "New Prodrugs of 9-(2-Phosphonomethoxyethyl) Adenine [PMEA]: Synthesis and Stability Studies", 14(3-5):563-565, NUCLS & NUCLT, 1995
	Cannon, Joseph G. (Reviewer), "The Chemistry of the Carbonyl Group", Vol. II, Edited by Saul Patai, Book Review, Sep-1966
	Davidson et al., "N-(Acyloxyalkyl)pyridinium Salts as Soluble Prodrugs of a Potent Platelet Activating Factor Antagonist", 37(26):4423-4429, J MED CHEM, 23-Dec-1994
	Engel, R., "Phosphonates as Analogues of Natural Phosphates", 77(3):349-367, CHEM REV, 1977
	Farquhar et al., "Biologically Reversible Phosphate-Protective Groups", 72:324-325, J PHARM SCI, 1983
	Flaherty et al., "Synthesis and Selective Monoamine Oxidase B-Inhibiting Properties of 1-Methyl-1,2,3,6-tetrahydropyrid-4-yl Carbamate Derivatives: Potential Prodrugs of (R)- and (S)-Nordeprenyl", 39:4759-4761, J MED CHEM, 1996
	Folkman et al., "Acyloxymethyl Carbonochloridates. New Intermediates in Prodrug Synthesis", pp. 1159-1166, SYNTHESIS, Dec-1990
↓	Hammer et al., "Ether, Carbonate and Urethane Deoxynucleoside Derivatives as Prodrugs", 50:609-622, Acta Chemica Scandinavia, 1996
mla	Ikeda et al., "Studies on Prodrugs. III. A Convenient and Practical Preparation of Ampicillin Prodrugs", 32:4316-4322, CHEM PHARM BULL, 1984

EXAMINER	Michael G. Ambrose	DATE CONSIDERED	04/23/99
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO.: 221.P1C SERIAL NO.: 09/187,763
	APPLICANT: Arimilli et al.
	FILING DATE: 11/6/98 GROUP ART UNIT: 1614

(37 CFR 1.98(b))

EXAMR'S INITIALS	ARTICLE
<i>mala</i>	Iyer et al., "Synthesis of Acyloxyalkyl Acylphosphonates as Potential Prodrugs of the Antiviral, Trisodium Phosphonoformate (Foscarnet Sodium)", 30(51):7141-7144, TET LETT, 1989
↑	Jones et al., "Minireview: nucleotide prodrugs", 27:1-17, ANTIVIRAL RES, 1995
	Krise et al., "Prodrugs of phosphates, phosphonates, and phosphinates", 19:287-310, Advanced Drug Delivery Reviews, 22-May-1996
	Landgrebe, John A., "Crystallization and Filtration", 3rd edition, pp. 65-77, Theory and Practice in the Organic Laboratory, 1982
	Lindahl et al., "Synthesis of an Acyloxymethyl Prodrug of the Inositol Phosphate Alpha-Trinositol", 15(5):549-554, J CARBOHYDRATE CHEMISTRY, 1996
	Maillard et al., "Adenosine Receptor Prodrugs: Synthesis and Biological Activity of Derivatives of Potent, A1-Selective Agonists", 83(1):46-53, J PHARM SCI, Jan-1994
	Myerson, Allan S. (editor), "Solutions and Solution Properties", p. 1 - 165, Handbook of Industrial Crystallization, 1993
	Naesens et al., "Antiretroviral Activity and Pharmacokinetics in Mice of Oral Bis(Pivaloyloxymethyl)-9-(2-Phosphonylmethoxyethyl)Adenine, the Bis(Pivaloyloxymethyl) Ester Prodrug of 9-(2-Phosphonylmethoxyethyl)Adenine", 40(1):22-28, ANTIMICRO AG & CHEMO, Jan-1996
	Robinson et al., "Discovery of the Hemifumarate and (alpha-L-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group", 39:10-18, J MED CHEM, 1996
	Safadi et al., "Phosphoryloxymethyl Carbamates and Carbonates--Novel Water-Soluble Prodrugs for Amines and Hindered Alcohols", 10(9):1350-1355, PHARM RES, 1993
	Sakamoto et al., "Studies on Prodrugs. II. Preparation and Characterization of (5-Substituted 2-Oxo-1,3-dioxolen-4-yl)methyl Esters of Ampicillin", 32(6):2241-2248, CHEM PHARM BULL, 19-Aug-1983
	Samara et al., "Pharmacokinetic Analysis of Diethylcarbonate Prodrugs of Ibuprofen and Naproxen", 16:201-210, Biopharmaceutics & Drug Disposition, 1995
	Shaw et al., "Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in Dogs", 14(12):1824-1829, PHARM RES, 1997
	Srinivas et al., "Metabolism and In Vitro Antiretroviral Activities of Bis(Pivaloyloxymethyl) Prodrugs of Acyclic Nucleoside Phosphonates", 37(10):2247-2250, ANTIMICRO AG & CHEMO, Oct-1993
	Srivastva et al., "Bioreversible Phosphate Protective Groups: Synthesis and Stability of Model Acyloxymethyl Phosphates", 12:118-129, BIOORG CHEM, 1984
	Starrett et al., "Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine", 19:267-273, ANTIVIRAL RES, 1992
↓	Starrett et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)", 37:1857-1864, J MED CHEM, 1994
<i>mala</i>	Sueoka et al., "Pharmacokinetics of Alkoxy carbonyloxy Ester Prodrugs of PMPA in Dogs", Abstract, American Association of Pharmaceutical Science, Western Regional Meeting, April 24-25, 1997,

EXAMINER	Michael G. Ambrose	DATE CONSIDERED	<u>04/23/99</u>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**
**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(37 CFR 1.98(b))

ATTY DOCKET NO.: 221.P1C SERIAL NO.: 09/187,763

APPLICANT: Arimilli et al.

FILING DATE: 11/6/98

GROUP ART UNIT: 1614

EXAMR'S INITIALS	ARTICLE
<i>mla</i>	Sueoka et al., "Pharmacokinetics of Alkoxy carbonyloxy Ester Prodrugs of PMPA in Dogs", Poster, American Association of Pharmaceutical Science, Western Regional Meeting, April 24-25, 1997,
↑	Tsai et al., "Effects of (R)-9-(2-Phosphonylmethoxypropyl)adenine Monotherapy on Chronic SIV Infection in Macaques", 13(8):707-712, AIDS RES & HUM RETRO, 1997
↓	Tsai et al., "Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine", 270:1197-1199, SCIENCE, 17-Nov-1995
<i>mla</i>	Weller et al., "Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes a Prodrugs of Amidines", 39:3139-3147, J MED CHEM, 20-Dec-1995

EXAMINER

Michael G. Ambrose

DATE CONSIDERED

04/23/99

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.